“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, October 31, 2018: Pharma major Lupin Limited reported its financial performance for the second quarter and six months ended September 30th, 2018. These results were taken on record by the Board of Directors at a meeting held in Mumbai today.
Key Financial & Performance Highlights
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “This quarter we saw promising developments on the specialty front with the Solosec launch in full swing and a positive CHMP opinion for NaMuscla. Aided by forex and markets like the US starting to stabilize, we are now getting back on growth mode. We have made meaningful progress on our cost optimization efforts and these should start playing out from the next fiscal. Our growth will be fueled by new product launches in the near term and meaningful evolution of products in the complex generic, biosimilar and specialty space in the mid to long-term.”
Consolidated Unaudited Financial Results – Quarter II, FY2019
Amount in Rs. m.
Income Statement highlights – Q2 FY2019
Balance Sheet highlights
Rs. 56,395 m. as on June 30th, 2018. The working capital number of days stands at 141 days as on September 30th, 2018 compared to 133 days as on June 30th, 2018.
Lupin's North America sales for Q2 FY2019 were Rs. 12,487 m. compared sales of Rs. 11,858 m. during Q1 FY2019 and Rs. 13,611 m. during Q2 FY2018; accounting for 32% of Lupin's global sales.
Lupin's India formulation sales for Q2 FY2019 grew by 0.9% to Rs. 12,032 m. as compared to Rs. 11,924 m. in Q1 FY2019 and by 3.8% as compared to Rs 11,593 m. in Q2 FY2018.
India formulation sales for H1 FY2019 grew by 14.5% to Rs. 23,956 m. as compared to Rs. 20,918 m. during H1 FY2018.
Lupin is the 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).
Lupin's APAC sales were at Rs. 6,199 m. during Q2 FY2019 compared to sales of Rs. 6,077 m. in Q1 FY2019 and Rs. 6,357 m. in Q2 FY2018.
Lupin's Japan sales were JPY 8,151 m. during Q2 FY2019 compared to JPY 8,129 m. in Q1 FY2019 and JPY 8,685 m. in Q2 FY2018.
Lupin remains the 6th largest generic player in Japan (IQVIA MAT September 2018).
Lupin's Philippines sales were PHP 383 m. during Q2 FY2019 compared to PHP 352 m. in Q1 FY2019 and PHP 504 m. in Q2 FY2018.
Europe, Middle-East and Africa (EMEA)
Lupin's EMEA sales were Rs. 2,949 m for Q2 FY2019 compared to sales of Rs. 2,760 m. in Q1 FY2019 and Rs. 2,758 m. in Q2 FY2018.
Lupin's South Africa sales were ZAR 283 m. during Q2 FY2019 compared to ZAR 261 m. in Q1 FY2019 an ZAR 270 m. in Q2 FY2018.
Lupin remains the 4th largest generic player in the South African market (IQVIA MAT September 2018).
Lupin's Germany sales were Euro 7.3 m. during Q2 FY2019 compared to Euro 7.5 m. in Q1 FY2019 and Euro 7.6 m. in Q2 FY2018.
Latin America (LATAM)
Lupin's LATAM sales were Rs. 1,459 m. during Q2 FY2019 compared to Rs. 1,256 m. in Q1 FY2019 and Rs. 1,395 m. in Q2 FY2018.
Lupin's Brazil sales were BRL 42 m. during Q2 FY2019 compared to BRL 25 m. in Q1 FY2019 and BRL 40 m. in Q2 FY2018.
Lupin's Mexico sales were MXN 164 m. during Q2 FY2019 compared to MXN 159 m. in Q1 FY2019 and MXN 154 m. in Q2 FY2018.
Global API sales were Rs. 3,347 m. during Q2 FY2019 as compared to Rs. 3,581 m. during Q1 FY2019 and Rs. 2,650 m. during Q2 FY2018; accounting for 9% of Lupin's global sales.
Global API sales for H1 FY2019 grew by 27.3% to Rs. 6,928 m. as compared to Rs. 5,442 m. during H1 FY2018.
Research and Development
Revenue Expenditure on R&D during Q2 FY2019 amounted to Rs. 3,758 m., 9.7% of sales as against Rs. 3,753 m., 9.9% of sales during Q1 FY2019 and Rs. 4,739 m., 12.2% of sales during Q2 FY2018.
Lupin filed 4 ANDA and received 7 approvals from the US FDA during the quarter. Cumulative ANDA filings with the US FDA stood at 405 as of September 30th, 2018, with the company having received 247 approvals to date.
The Company now has 39 First-to-Files (FTF) filings including 14 exclusive FTF opportunities. Cumulative DMF filings stands at 192 as of September 30th, 2018.
Cumulative filings with European authorities now stands at 59 with the company having received 57 approvals to date.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 13th largest generics pharmaceutical company in terms of market capitalization (30th September 2018, Bloomberg) and the 8th largest generics pharmaceutical company in terms of revenues (30th June 2018, Bloomberg LTM) globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT September 2018); 3rd largest Indian pharmaceutical company by global revenues (30th June 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan (IQVIA MAT September 2018) and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).
For the financial year ended 31st March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
Safe Harbor Statement